Cardiovascular adverse events of ibrutinib

被引：14
作者：
Ahn, Inhye E. [1 ]
机构：
[1] NHLBI, Bldg 10, Bethesda, MD 20892 USA
来源：
BLOOD | 2019年 / 134卷 / 22期
关键词：
D O I：
10.1182/blood.2019002805
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Dickerson et al report on the increased incidence and worsening severity of hypertension and its association with cardiovascular outcomes in 562 patients treated with ibrutinib for B-cell malignancies.(1)
引用
收藏
页码：1881 / 1882
页数：2
相关论文
共 10 条
  • [1] Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
    Barr, Paul M.
    Robak, Tadeusz
    Owen, Carolyn
    Tedeschi, Alessandra
    Bairey, Osnat
    Bartlett, Nancy L.
    Burger, Jan A.
    Hillmen, Peter
    Coutre, Steven
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jianyong
    Simpson, David
    Offner, Fritz
    Moreno, Carol
    Zhou, Cathy
    Styles, Lori
    James, Danelle
    Kipps, Thomas J.
    Ghia, Paolo
    [J]. HAEMATOLOGICA, 2018, 103 (09) : 1502 - 1510
  • [2] Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
    Byrd, John C.
    Hillmen, Peter
    O'Brien, Susan
    Barrientos, Jacqueline C.
    Reddy, Nishitha M.
    Coutre, Steven
    Tam, Constantine S.
    Mulligan, Stephen P.
    Jaeger, Ulrich
    Barr, Paul M.
    Furman, Richard R.
    Kipps, Thomas J.
    Thornton, Patrick
    Moreno, Carol
    Montillo, Marco
    Pagel, John M.
    Burger, Jan A.
    Woyach, Jennifer A.
    Dai, Sandra
    Vezan, Remus
    James, Danelle F.
    Brown, Jennifer R.
    [J]. BLOOD, 2019, 133 (19) : 2031 - 2042
  • [3] Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
    Chen, Jun
    Kinoshita, Taisei
    Sukbuntherng, Juthamas
    Chang, Betty Y.
    Elias, Laurence
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 2835 - 2844
  • [4] Hypertension and incident cardiovascular events following ibrutinib initiation
    Dickerson, Tyler
    Wiczer, Tracy
    Waller, Allyson
    Philippon, Jennifer
    Porter, Kyle
    Haddad, Devin
    Guha, Avirup
    Rogers, Kerry A.
    Bhat, Seema
    Byrd, John C.
    Woyach, Jennifer A.
    Awan, Farrukh
    Addison, Daniel
    [J]. BLOOD, 2019, 134 (22) : 1919 - 1928
  • [5] Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
    Dubovsky, Jason A.
    Beckwith, Kyle A.
    Natarajan, Gayathri
    Woyach, Jennifer A.
    Jaglowski, Samantha
    Zhong, Yiming
    Hessler, Joshua D.
    Liu, Ta-Ming
    Chang, Betty Y.
    Larkin, Karilyn M.
    Stefanovski, Matthew R.
    Chappell, Danielle L.
    Frissora, Frank W.
    Smith, Lisa L.
    Smucker, Kelly A.
    Flynn, Joseph M.
    Jones, Jeffrey A.
    Andritsos, Leslie A.
    Maddocks, Kami
    Lehman, Amy M.
    Furman, Richard
    Sharman, Jeff
    Mishra, Anjali
    Caligiuri, Michael A.
    Satoskar, Abhay R.
    Buggy, Joseph J.
    Muthusamy, Natarajan
    Johnson, Amy J.
    Byrd, John C.
    [J]. BLOOD, 2013, 122 (15) : 2539 - 2549
  • [6] The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
    Leong, Darryl P.
    Caron, Francois
    Hillis, Christopher
    Duan, Annie
    Healey, Jeff S.
    Fraser, Graeme
    Siegal, Deborah
    [J]. BLOOD, 2016, 128 (01) : 138 - 140
  • [7] Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
    O'Brien, Susan
    Furman, Richard R.
    Coutre, Steven
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie
    Sharman, Jeff
    Wierda, William
    Jones, Jeffrey
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Luan, Ying
    James, Danelle F.
    Chu, Alvina D.
    Byrd, John C.
    [J]. BLOOD, 2018, 131 (17) : 1910 - 1919
  • [8] Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
    O'Brien, Susan
    Jones, Jeffrey A.
    Coutre, Steven E.
    Mato, Anthony R.
    Hillmen, Peter
    Tam, Constantine
    Osterborg, Anders
    Siddiqi, Tanya
    Thirman, Michael J.
    Furman, Richard R.
    Ilhan, Osman
    Keating, Michael J.
    Call, Timothy G.
    Brown, Jennifer R.
    Stevens-Brogan, Michelle
    Li, Yunfeng
    Clow, Fong
    James, Danelle F.
    Chu, Alvina D.
    Hallek, Michael
    Stilgenbauer, Stephan
    [J]. LANCET ONCOLOGY, 2016, 17 (10) : 1409 - 1418
  • [9] Whelton PK, 2018, HYPERTENSION, V71, pE13, DOI [10.1161/HYP.0000000000000065, 10.1161/HYP.0000000000000066]
  • [10] Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
    Woyach, J. A.
    Ruppert, A. S.
    Heerema, N. A.
    Zhao, W.
    Booth, A. M.
    Ding, W.
    Bartlett, N. L.
    Brander, D. M.
    Barr, P. M.
    Rogers, K. A.
    Parikh, S. A.
    Coutre, S.
    Hurria, A.
    Brown, J. R.
    Lozanski, G.
    Blachly, J. S.
    Ozer, H. G.
    Major-Elechi, B.
    Fruth, B.
    Nattam, S.
    Larson, R. A.
    Erba, H.
    Litzow, M.
    Owen, C.
    Kuzma, C.
    Abramson, J. S.
    Little, R. F.
    Smith, S. E.
    Stone, R. M.
    Mandrekar, S. J.
    Byrd, J. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) : 2517 - 2528
1